Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myelomaTom Martin, Imtiaz A. Samjoo, Carolyn C. Jackson et al.|Current Medical Research and Opinion|2021Cited by 49
Updated results from a matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myelomaTom Martin, Imtiaz A. Samjoo, Saad Z. Usmani et al.|Current Medical Research and Opinion|2022Cited by 25